Works by Joo Hyuk Sohn


Results: 29
    1
    2
    3
    4
    5

    Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-37768-3
    By:
    • Bae, Mingyun;
    • Kim, Gyuhee;
    • Lee, Tae-Rim;
    • Ahn, Jin Mo;
    • Park, Hyunwook;
    • Park, Sook Ryun;
    • Song, Ki Byung;
    • Jun, Eunsung;
    • Oh, Dongryul;
    • Lee, Jeong-Won;
    • Park, Young Sik;
    • Song, Ki-Won;
    • Byeon, Jeong-Sik;
    • Kim, Bo Hyun;
    • Sohn, Joo Hyuk;
    • Kim, Min Hwan;
    • Kim, Gun Min;
    • Chie, Eui Kyu;
    • Kang, Hyun-Cheol;
    • Kong, Sun-Young
    Publication type:
    Article
    6
    7
    8
    9

    A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial.

    Published in:
    International Journal of Cancer, 2018, v. 143, n. 12, p. 3240, doi. 10.1002/ijc.31651
    By:
    • Park, Yeon Hee;
    • Lee, Kyung‐Hun;
    • Sohn, Joo Hyuk;
    • Lee, Keun Seok;
    • Jung, Kyung Hae;
    • Kim, Jee‐Hyun;
    • Lee, Ki Hyeong;
    • Ahn, Jin Seok;
    • Kim, Tae‐Yong;
    • Kim, Gun Min;
    • Park, In Hae;
    • Kim, Sung‐Bae;
    • Kim, Se Hyun;
    • Han, Hye Sook;
    • Im, Young‐Hyuck;
    • Ahn, Jin‐Hee;
    • Kim, Jung‐Yong;
    • Kang, Jahoon;
    • Im, Seock‐Ah
    Publication type:
    Article
    10
    11
    12
    13
    14
    15

    In Reply.

    Published in:
    Oncologist, 2021, v. 26, n. 7, p. e1286, doi. 10.1002/onco.13782
    By:
    • Rugo, Hope S.;
    • Huober, Jens;
    • Garcia‐Saenz, Jose A.;
    • Masuda, Norikazu;
    • Sohn, Joo Hyuk;
    • Andre, Valerie A.M.;
    • Barriga, Susana;
    • Cox, Joanne;
    • Goetz, Matthew
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.

    Published in:
    Breast Cancer (13406868), 2024, v. 31, n. 5, p. 858, doi. 10.1007/s12282-024-01600-7
    By:
    • Yamashita, Toshinari;
    • Sohn, Joo Hyuk;
    • Tokunaga, Eriko;
    • Niikura, Naoki;
    • Park, Yeon Hee;
    • Lee, Keun Seok;
    • Chae, Yee Soo;
    • Xu, Binghe;
    • Wang, Xiaojia;
    • Im, Seock-Ah;
    • Li, Wei;
    • Lu, Yen-Shen;
    • Aguilar, Cecilia Orbegoso;
    • Nishijima, Soichiro;
    • Nishiyama, Yuji;
    • Sugihara, Masahiro;
    • Modi, Shanu;
    • Tsurutani, Junji
    Publication type:
    Article
    25
    26

    Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.

    Published in:
    Breast Cancer Research & Treatment, 2024, v. 204, n. 2, p. 237, doi. 10.1007/s10549-023-07165-x
    By:
    • Balmaña, Judith;
    • Fasching, Peter A.;
    • Couch, Fergus J.;
    • Delaloge, Suzette;
    • Labidi-Galy, Intidhar;
    • O'Shaughnessy, Joyce;
    • Park, Yeon Hee;
    • Eisen, Andrea F.;
    • You, Benoit;
    • Bourgeois, Hughes;
    • Gonçalves, Anthony;
    • Kemp, Zoe;
    • Swampillai, Angela;
    • Jankowski, Tomasz;
    • Sohn, Joo Hyuk;
    • Poddubskaya, Elena;
    • Mukhametshina, Guzel;
    • Aksoy, Sercan;
    • Timcheva, Constanta V.;
    • Park-Simon, Tjoung-Won
    Publication type:
    Article
    27
    28

    Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).

    Published in:
    Cancer Research & Treatment, 2019, v. 51, n. 1, p. 43, doi. 10.4143/crt.2017.562
    By:
    • In Hae Park;
    • Seock-Ah Im;
    • Kyung Hae Jung;
    • Joo Hyuk Sohn;
    • Yeon Hee Park;
    • Keun Seok Lee;
    • Sung Hoon Sim;
    • Kyong-Hwa Park;
    • Jee Hyun Kim;
    • Byung Ho Nam;
    • Hee-Jun Kim;
    • Tae-Yong Kim;
    • Kyung-Hun Lee;
    • Sung-Bae Kim;
    • Jin-Hee Ahn;
    • Suee Lee;
    • Jungsil Ro
    Publication type:
    Article
    29

    Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.

    Published in:
    Cancer Research & Treatment, 2016, v. 48, n. 4, p. 1373, doi. 10.4143/crt.2015.475
    By:
    • Se Hyun Kim;
    • Kyung Hae Jung;
    • Tae-Yong Kim;
    • Seock-Ah Im;
    • In Sil Choi;
    • Yee Soo Chae;
    • Sun Kyung Baek;
    • Seok Yun Kang;
    • Sarah Park;
    • In Hae Park;
    • Keun Seok Lee;
    • Yoon Ji Choi;
    • Soohyeon Lee;
    • Joo Hyuk Sohn;
    • Yeon-Hee Park;
    • Young-Hyuck Im;
    • Jin-Hee Ahn;
    • Sung-Bae Kim;
    • Jee Hyun Kim
    Publication type:
    Article